Previous close | 37.99 |
Open | 39.24 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 39.24 - 39.50 |
52-week range | 39.24 - 39.50 |
Volume | |
Avg. volume | N/A |
Market cap | 2.033M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 0.30 |
EPS (TTM) | 1.30 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Conference/MiscellaneousEckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA 30.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of rad
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): PersonnelReorganization in the Executive Board of Eckert & Ziegler 15.05.2023 / 09:27 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, May 15, 2023. The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, an
Eckert & Ziegler Strahlen- und Medizintechnik ( ETR:EUZ ) First Quarter 2023 Results Key Financial Results Revenue...
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter ResultsEckert & Ziegler with Strong Sales Growth in the First Quarter of 2023 11.05.2023 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 11 May 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): AllianceEckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate 08.05.2023 / 11:15 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 8 May 2023 – Following clinical investigations of hypertension specialists in the Netherlands, France, the United States, and China, the
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter ResultsEckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance25-Apr-2023 / 17:59 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, April 25, 2023. A
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): MiscellaneousEckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177 20.04.2023 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added L
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): ExpansionEckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site 12.04.2023 / 15:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 12 April 2023 – Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA) from the Department of Ecology and Environment of Ji
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Incoming OrdersEckert & Ziegler to Supply POINT Biopharma with Actinium-225 04.04.2023 / 14:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carr
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Annual Results/ForecastEckert & Ziegler: Successful fiscal year 2022 30.03.2023 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20%
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): MiscellaneousEckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE) 24.03.2023 / 16:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 24 March 2023. The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Dividend/Annual ResultsEckert & Ziegler with Unchanged Dividend Proposal 23.03.2023 / 18:33 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 23 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed FY 2022 with sales of 222.3 million EUR. Net income for the year rose by around 20% compared to the previous year's figure adjusted for special effects and reached 29.3 million
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): MiscellaneousEckert & Ziegler Submits Drug Master File for Lu-177 n.c.a. 03.03.2023 / 10:15 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 3 March 2023. Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetiu
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance/StudyLausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting 01.02.2023 / 10:35 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflamma
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Preliminary ResultsEckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures17-Jan-2023 / 12:47 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, 17 January 2023. According to preliminary, unaudited figures, Eckert &
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): PersonnelChange in the Supervisory Board of Eckert & Ziegler AG 20.12.2022 / 18:31 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 20.12.2022. Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). She replaces sinologist Jutta Ludw
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): PersonnelChanges in the Management Board of Eckert & Ziegler19-Dec-2022 / 13:29 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, 19.12.2022. The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyEckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR25-Nov-2022 / 15:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Berlin, 25 November 2022. PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX),
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9 Month figuresEckert & Ziegler: Nine-Month Figures Show Strong Sales Growth 08.11.2022 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 8 November 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in th
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyFirst CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial 27.10.2022 / 10:59 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial. Code named PTF202, the clinical exami
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Incoming OrdersEckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement 13.10.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, 13 October 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) and Alpha-9 Theranostics Inc. (Alpha-9), a radiopharmaceutical company with offices in Vancouver and Boston, have signed an agreement for the preferred supply
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Incoming OrdersEckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility 11.10.2022 / 14:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, Germany and BELOIT, Wis., 11 October 2022 - Eckert & Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Ec
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Results/Quarterly / Interim StatementEckert & Ziegler with Successful First Half of 2022 11.08.2022 / 07:45 The issuer is solely responsible for the content of this announcement.Berlin, 11 August 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 19% to EUR 106.8 million in the first half of the year. At EUR 15.4 million, net income was down on the same per
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): ContractEckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures 04.08.2022 / 10:07 The issuer is solely responsible for the content of this announcement.BERLIN, GERMANY, August 04, 2022 – Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) and member of a pan-European consortium
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year ResultsEckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter27-Jul-2022 / 12:53 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Insider information pursuant to Article 17 MA Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2